Terminated
A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors
I9L-MC-JZCA - ClinicalTrials.gov - NCT03343613
The purpose of this study is to evaluate the safety of the study drug LY3381916 administered alone or in combination with anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody (LY3300054).
How long will I be in the trial?
Your participation in this trial could last up to 24 months, depending on your cancer type and how you and your tumor respond.
Terminated
A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors
I9L-MC-JZCA - ClinicalTrials.gov - NCT03343613
The purpose of this study is to evaluate the safety of the study drug LY3381916 administered alone or in combination with anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody (LY3300054).
How long will I be in the trial?
Your participation in this trial could last up to 24 months, depending on your cancer type and how you and your tumor respond.
Key Requirements
Age :
18+
Sex:
All
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18+
Sex
All
Participants must
Participants must have a diagnosis of cancer (solid tumor) that has spread to other parts of the body
Participants must be willing to provide required, newly acquired tumor biopsies (doctor removes a small amount of tissue)
Participants must NOT
Participants must not have cancer that has spread to the brain
Participants must not have an HIV infection or hepatitis B or C
Participants must not have previously received an indoleamine- 2,3-dioxygenase (IDO) inhibitor
Participants must not have an active autoimmune disease or currently require immunosuppression of >10 milligrams of prednisone or equivalent per day
Participants must not have lung disease or inflammation of the lungs or a history of lung inflammation that required steroids
Trial Summary
Conditions the trial is for
Solid Tumor
What the trial is testing?
LY3381916, LY3300054
Could I receive a Placebo?
no
Enrollment Goal
290
Trial Dates
November 2017 - May 2020
Trial Phase
1
Enter your postal code to find the nearest site
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18+
Sex
All
Participants must
Participants must have a diagnosis of cancer (solid tumor) that has spread to other parts of the body
Participants must be willing to provide required, newly acquired tumor biopsies (doctor removes a small amount of tissue)
Participants must NOT
Participants must not have cancer that has spread to the brain
Participants must not have an HIV infection or hepatitis B or C
Participants must not have previously received an indoleamine- 2,3-dioxygenase (IDO) inhibitor
Participants must not have an active autoimmune disease or currently require immunosuppression of >10 milligrams of prednisone or equivalent per day
Participants must not have lung disease or inflammation of the lungs or a history of lung inflammation that required steroids
Trial Summary
Conditions the trial is for
Solid Tumor
What the trial is testing?
LY3381916, LY3300054
Could I receive a Placebo?
no
Enrollment Goal
290
Trial Dates
November 2017 - May 2020
Trial Phase
1
Not the right fit? Sign up to receive updates on new Solid Tumor trials.
Trial Locations
Hide locations not currently recruiting
Enter your postal code to see sites near you
By clicking the checkbox and using the map, you agree to allow Google Maps to collect your personal information in accordance with their Privacy Policy
Solid Tumor Resources
